PT-141

Common questions about PT-141

What is PT-141?

PT-141 (bremelanotide) is a synthetic α-MSH analog that activates the melanocortin-4 receptor centrally. It is approved clinically as Vyleesi for hypoactive sexual desire disorder in premenopausal women.

Is PT-141 FDA-approved?

Yes — under the brand name Vyleesi (bremelanotide) for hypoactive sexual desire disorder. The unbranded research-grade compound sold by peptide vendors is not the FDA-approved finished product and is intended for research use only.

What is the half-life of PT-141?

Published clinical pharmacokinetics report a half-life of approximately 2.7 hours, with a reported range of roughly 1.9–4.0 hours after subcutaneous administration.

What dose of PT-141 is used in research?

The clinically approved bremelanotide dose for HSDD is documented in the FDA prescribing information. Pepticker does not publish a dosing recommendation — clinical use requires a prescription, and research protocols should follow the original published study.

How is PT-141 different from melanotan II?

PT-141 is a more selective melanocortin-receptor agonist (with stronger MC4R activity and weaker pigmentation effects) compared to melanotan II, which is a non-selective melanocortin agonist studied primarily for tanning and arousal.

Is PT-141 legal?

In the US, PT-141 is a prescription compound when used clinically (as Vyleesi); the unbranded form is sold for research use. In Canada and the UK research-chemical vendors supply it for laboratory use. In Australia it is TGA Schedule 4 and prescription-only when used clinically. Status is informational — not legal advice.

Editorial summary of published research. Not medical advice. See /methodology for sourcing.